骨髓间充质干细胞治疗肝衰竭的作用机制

doi:10.16352/j.issn.1001-6325.2024.11.1608

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (11): 1608-1612.doi: 10.16352/j.issn.1001-6325.2024.11.1608

骨髓间充质干细胞治疗肝衰竭的作用机制

齐泽强, 郭庭煜, 吴治念, 王亚东^*

河北医科大学第三医院感染科,河北石家庄 050051

收稿日期:2023-10-31 修回日期:2024-05-08 出版日期:2024-11-05 发布日期:2024-10-31
通讯作者: ^*wangyadong@hebmu.edu.cn
基金资助:
河北省自然科学基金(H2023206042);河北省政府临床医学优秀人才培养计划(ZF2023082)

Mechanism of bone marrow-derived mesenchymal stem cells in the treatment of liver failure

QI Zeqiang, GUO Tingyu, WU Zhinian, WANG Yadong^*

Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China

Received:2023-10-31 Revised:2024-05-08 Online:2024-11-05 Published:2024-10-31
Contact: ^*wangyadong@hebmu.edu.cn

摘要/Abstract

摘要： 肝衰竭是临床一类急危重症肝病。骨髓间充质干细胞(BM-MSCs)具有向肝细胞分化、促进肝细胞再生,以及抑制肝细胞凋亡、坏死和炎性反应等作用,有助于修复受损的肝组织,改善肝功能,成为当前肝衰竭细胞治疗策略中极具应用潜力的一种新选择。

关键词: 肝衰竭, 间充质干细胞, 再生, 移植

Abstract: Liver failure is a kind of acute and severe liver disease. Bone marrow-derived mesenchymal stem cells (BM-MSCs) have the function of differentiating into hepatocytes. Promotion of the regeneration of hepatocytes regeneration, inhibition of apoptosis, necrosis and inflammation of hepatocytes, may facilitate repairing damaged liver tissue and improving liver function. BM-MSCs have become a new choice with great application potential in the treatment of liver failure.

Key words: liver failure, mesenchymal stem cell, regeneration, transplantation

中图分类号:

R575.3

齐泽强, 郭庭煜, 吴治念, 王亚东. 骨髓间充质干细胞治疗肝衰竭的作用机制[J]. 基础医学与临床, 2024, 44(11): 1608-1612.

QI Zeqiang, GUO Tingyu, WU Zhinian, WANG Yadong. Mechanism of bone marrow-derived mesenchymal stem cells in the treatment of liver failure[J]. Basic & Clinical Medicine, 2024, 44(11): 1608-1612.

参考文献

[1] Wesley BT, Ross ADB, Muraro D, et al. Single-cell atlas of human liver development reveals pathways directing hepatic cell fates[J]. Nat Cell Biol, 2022, 24: 1487-1498. doi:10.1038/s41556-022-00989-7.
[2] Purwaningrum M, Jamilah NS, Purbantoro SD, et al. Comparative characteristic study from bone marrow-derived mesenchymal stem cells[J]. J Vet Sci, 2021, 22: e74. doi:10.4142/jvs.2021.22.e74.
[3] Petrenko Y, Vackova I, Kekulova K, et al. A compara-tive analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential[J]. Sci Rep, 2020, 10: 4290. doi:10.1038/s41598-020-61167-z.
[4] Wang H, Yao W, Wang Y, et al. Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure[J]. Stem Cell Res Ther, 2023, 14: 267. doi: 10.1186/s13287-023-03494-2.
[5] Schacher FC, Martins Pezzi da Silva A, Silla L, et al. Bone marrow mesenchymal stem cells in acute-on-chronic liver failure grades 2 and 3: a phase I-II randomized clinical trial[J]. Can J Gastroenterol Hepatol, 2021, 2021: 3662776. doi:10.1155/2021/3662776.
[6] Aithal AP, Bairy LK, Seetharam RN, et al. Hepatoprotective effect of bone marrow-derived mesenchymal stromal cells in CCl(4)-induced liver cirrhosis[J]. 3 Biotech, 2021, 11: 107. doi:10.1007/s13205-021-02640-y.
[7] Shi H, Wang X, Li F, et al. CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis[J]. Sci Transl Med, 2022, 14: eabp8309. doi:10.1126/scitranslmed.abp8309.
[8] Sheng M, Lin Y, Xu D, et al. CD47-mediated hedgehog/SMO/GLI1 signaling promotes mesenchymal stem cell immunomodulation in mouse liver inflammation[J]. Hepatology, 2021, 74: 1560-1577. doi:10.1002/hep.31831.
[9] Garg A, Khan S, Luu N, et al. TGFβ1 priming enhances CXCR3-mediated mesenchymal stromal cell engraftment to the liver and enhances anti-inflammatory efficacy[J]. J Cell Mol Med, 2023, 27: 864-878. doi:10.1111/jcmm.17698.
[10] Li C, Jin Y, Wei S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J]. Hepatology, 2019, 70: 1714-1731. doi:10.1002/hep.30700.
[11] Watanabe Y, Fukuda T, Hayashi C, et al. Extracellular vesicles derived from GMSCs stimulated with TNF-α and IFN-α promote M2 macrophage polarization via enhanced CD73 and CD5L expression[J]. Sci Rep, 2022, 12: 13344. doi:10.1038/s41598-022-17692-0.
[12] Wan YM, Li ZQ, Zhou Q, et al. Mesenchymal stem cells alleviate liver injury induced by chronic-binge ethanol feeding in mice via release of TSG6 and suppression of STAT3 activation[J]. Stem Cell Res Ther, 2020, 11: 24. doi:10.1186/s13287-019-1547-8.
[13] Kulesza A, Paczek L, Burdzinska A. The role of COX-2 and PGE2 in the regulation of immunomodulation and other functions of mesenchymal stromal cells[J]. Biomedicines, 2023, 11. doi:10.3390/biomedicines11020445.
[14] Zhang Y, Zhangdi H, Nie X, et al. Exosomes derived from BMMSCs mitigate the hepatic fibrosis via anti-pyroptosis pathway in a cirrhosis model[J]. Cells, 2022, 11. doi:10.3390/cells11244004.
[15] Luo XY, Meng XJ, Cao DC, et al. Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes[J]. Stem Cell Res Ther, 2019, 10: 16. doi:10.1186/s13287-018-1122-8.
[16] Li YH, Shen S, Shao T, et al. Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6C(hi/lo) macrophages through activating the cytokine-paracrine and apoptotic pathways[J]. Cell Death Discov, 2021, 7: 239. doi:10.1038/s41420-021-00584-z.
[17] Ma L, Wei J, Zeng Y, et al. Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J]. Drug Deliv, 2022, 29: 440-453. doi:10.1080/10717544.2022.2030428.
[18] Takeuchi S, Tsuchiya A, Iwasawa T, et al. Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis[J]. NPJ Regen Med, 2021, 6: 19. doi:10.1038/s41536-021-00132-4.
[19] Xu J, Chen P, Yu C, et al. Hypoxic bone marrow mesenchymal stromal cells-derived exosomal miR-182-5p promotes liver regeneration via FOXO1-mediated macrophage polarization[J]. FASEB J, 2022, 36: e22553. doi:10.1096/fj.202101868RRR.
[20] Zhang J, Gao J, Li X, et al. Bone marrow mesenchymal stem cell-derived small extracellular vesicles promote liver regeneration via miR-20a-5p/PTEN[J]. Front Pharmacol, 2023, 14: 1168545. doi:10.3389/fphar.2023.1168545.
[21] Lin D, Chen H, Xiong J, et al. Mesenchymal stem cells exosomal let-7a-5p improve autophagic flux and alleviate liver injury in acute-on-chronic liver failure by promoting nuclear expression of TFEB[J]. Cell Death Dis, 2022, 13: 865. doi:10.1038/s41419-022-05303-9.
[22] Heo SK, Yu HM, Kim DK, et al. LIGHT (TNFSF14) promotes the differentiation of human bone marrow-derived mesenchymal stem cells into functional hepatocyte-like cells[J]. PLoS One, 2023, 18: e0289798. doi:10.1371/journal.pone.0289798.
[23] Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial[J]. Hepatology, 2017, 66: 209-219. doi:10.1002/hep.29189.
[24] Casiraghi F, Perico N, Podestà MA, et al. Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: a randomized controlled trial[J]. Am J Transplant, 2021, 21: 2795-2809. doi:10.1111/ajt.16468.
[25] Zhang Y, Zhang J, Yi H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase Ⅰ/Ⅱ randomized, open-label, controlled trial[J]. Stem Cell Res Ther, 2021, 12: 244. doi:10.1186/s13287-021-02246-4.

骨髓间充质干细胞治疗肝衰竭的作用机制

Mechanism of bone marrow-derived mesenchymal stem cells in the treatment of liver failure

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李佳铭, 杨超, 麻莉. 防治子宫内膜损伤的策略[J]. 基础医学与临床, 2024, 44(9): 1308-1313.
[2]	赵俊丽, 朱君君, 詹秋楠, 刘苗. 骨髓间充质干细胞来源外泌体抑制高糖诱导的腹膜间皮细胞EMT[J]. 基础医学与临床, 2024, 44(8): 1149-1156.
[3]	宋佳, 赵峰, 张婷, 徐静, 孙静莉, 陈震宇. 人羊膜间充质干细胞对大鼠子宫瘢痕的修复作用[J]. 基础医学与临床, 2024, 44(7): 1002-1007.
[4]	龚金涛, 厉建伟, 李玉恒, 李堑, 赵春华. 骨髓间充质干细胞缓解模拟微重力对小鼠大脑皮质的不利影响[J]. 基础医学与临床, 2024, 44(6): 772-778.
[5]	高竞溪, 赵晓妍, 朱星雨, 孙昭, 韩钦, 赵春华. BM-MSCs延缓CD8⁺初始T细胞衰老[J]. 基础医学与临床, 2024, 44(5): 683-689.
[6]	傅晨, 李平. 重型再生障碍性贫血治疗的研究进展[J]. 基础医学与临床, 2024, 44(5): 719-723.
[7]	李娜, 李涛, 杨冬梨, 姚媛. 和厚朴酚抑制人脂肪间充质干细胞增殖[J]. 基础医学与临床, 2024, 44(4): 483-488.
[8]	刘尚昆, 王红娟, 康晓静. 细胞移植联合其他治疗策略在治疗白癜风中的研究进展[J]. 基础医学与临床, 2024, 44(11): 1584-1588.
[9]	景光旭, 王张鹏, 刘忠钰, 吕双, 孙红玉. 低氧预处理胎盘间充质干细胞减轻重症急性胰腺炎模型小鼠胰腺组织损伤[J]. 基础医学与临床, 2023, 43(9): 1346-1352.
[10]	张亮亮, 赵程锦, 周煜虎, 曹博, 段明明, 冯阳阳. LncRNA FGD5-AS1调节miR-93-5p/BMP2轴促进人骨髓间充质干细胞成骨分化[J]. 基础医学与临床, 2023, 43(8): 1179-1185.
[11]	陈星星, 赛依帕, 胡筱霞, 王三萍, 罗璇, 刘璟. 人脐带间充质干细胞来源外泌体对脑瘫小鼠神经功能损伤的保护作用[J]. 基础医学与临床, 2023, 43(8): 1201-1207.
[12]	陈小坤, 包新杰, 高俊, 李永宁. 神经干细胞移植治疗阿尔兹海默病的机制研究进展[J]. 基础医学与临床, 2023, 43(7): 1148-1151.
[13]	李卓婷, 尚颖旭, 汪海燕, 蒋乔, 丁宝全, 李静, 赵春华. 间充质干细胞工程化的DNA纳米结构构建及其在小鼠肺组织靶向递送中的应用[J]. 基础医学与临床, 2023, 43(7): 1110-1116.
[14]	武文婧, 高竞溪, 赵晓妍, 孙昭, 韩钦, 赵春华. 芳香烃受体调控人脂肪间充质干细胞的免疫调节功能[J]. 基础医学与临床, 2023, 43(6): 889-897.
[15]	张燕萍, 姚刘旭, 丁倩男, 黄则勇, 李玉红, 黄素琴. 结直肠癌PDX模型成瘤率的影响因素及临床意义[J]. 基础医学与临床, 2023, 43(4): 596-602.